| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ML239 | CTRPv2 | pan-cancer | AAC | 0.16 | 3e-05 |
| mRNA | CD-437 | CTRPv2 | pan-cancer | AAC | 0.14 | 6e-05 |
| mRNA | LY-2183240 | CTRPv2 | pan-cancer | AAC | 0.13 | 6e-05 |
| mRNA | SCH-79797 | CTRPv2 | pan-cancer | AAC | 0.15 | 7e-05 |
| mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | -0.14 | 0.0001 |
| mRNA | FQI-1 | CTRPv2 | pan-cancer | AAC | 0.18 | 0.0003 |
| mRNA | neratinib | CTRPv2 | pan-cancer | AAC | -0.13 | 0.0004 |
| mRNA | pifithrin-alpha | CTRPv2 | pan-cancer | AAC | 0.14 | 0.0004 |
| mRNA | SN-38 | CTRPv2 | pan-cancer | AAC | 0.14 | 0.0004 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.12 | 0.0004 |